开发同时用于生物传感、肿瘤诊断和治疗的多功能纳米平台至关重要。在此，使用菠菜粉作为碳源和透明质酸（HA）作为靶向剂，通过一锅溶剂热法制备双发射荧光碳点（HA-CD）。所得HA-CD表现出优异的光学性能、良好的肿瘤靶向性和优异的光热转换性能。有趣的是，HA-CDs由于其固有的比率荧光特性，可以灵敏地感知极性环境的变化，并结合固有的靶向肿瘤能力实现肿瘤细胞的识别。更重要的是，HA-CD 具有 21.2% 的良好光热转换效率，有利于肿瘤的光热治疗。在 660 nm 激光照射后，与 HA-CD 一起孵育的 HeLa 细胞的存活率急剧下降至 14%，这表明 HA-CD 在体外具有显着的肿瘤抑制作用。值得注意的是，通过个体腹腔注射和瘤内注射，发现HA-CDs对激光照射的4T1荷瘤小鼠表现出类似的抑瘤作用，充分揭示了HA-CDs可以通过腹腔注射在肿瘤部位有效积累。此外，主要器官的离体组织病理学分析显示出良好的生物安全性。总的来说，这种设计的 HA-CD 策略为潜在的临床应用提供了一个新的多功能纳米平台。版权所有 © 2024。由 Elsevier B.V. 出版。

It is essential to develop a multifunctional nanoplatform for biosensing, tumor diagnosis and treatment simultaneously. Herein, dual-emission fluorescent carbon dots (HA-CDs) were fabricated via a one-pot solvothermal method using spinach powder as carbon source and hyaluronic acid (HA) as targeting agent. The obtained HA-CDs exhibited outstanding optical properties, good targeted tumor and excellent photothermal conversion performance. Interestingly, HA-CDs can sensitively perceive the changes in polar environments attributed to the inherent ratiometric fluorescence characteristics, and combined with the intrinsic targeting tumor ability achieved tumor cell recognition. More importantly, the HA-CDs possess good photothermal conversion efficiency of 21.2 % to be beneficial for photothermal therapy of tumors. The survival rate of HeLa cells incubated with HA-CDs dramatically decreased to 14 % after 660 nm laser irradiation, revealing the significant tumor inhibition of HA-CDs in vitro. Notably, through individual intraperitoneal and intratumoral injection, it was found that HA-CDs demonstrated a similar tumor suppressed effect on 4T1 tumor-bearing mice exposed to laser irradiation, fully uncovering that HA-CDs can efficiently accumulate at tumor site by intraperitoneal injection. Besides, the histopathological analysis of major organs ex vivo revealed a good biosafety profile. Collectively, this strategy of designed HA-CDs provides a new multifunctional nanoplatform for potential clinical application.Copyright © 2024. Published by Elsevier B.V.